ペプチド抗生物質市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、投与経路別、流通チャネル別、地域別、競合別、2020-2030年

ペプチド抗生物質の世界市場は、2024年に51億7,000万米ドルと評価され、2030年には76億7,000万米ドルに達すると予測され、予測期間中のCAGRは6.79%で成長すると予測されています。

ペプチド抗生物質は、抗菌特性を持つアミノ酸の短い鎖であり、様々な感染症の治療に使用されます。従来の低分子抗生物質とは異なり、ペプチド抗生物質はより大きなタンパク質様分子で構成され、膜破壊や細菌複製の妨害など多様なメカニズムで作用します。そのマルチ・ターゲット・アプローチは、耐性菌の可能性を低減し、抗菌薬耐性が高まる時代において重要な利点となります。メチシリン耐性黄色ブドウ球菌（MRSA）のような感染症の蔓延、人口の高齢化、外科手術の増加、ペプチド合成技術の向上などが、こうした薬剤の需要増につながっています。さらに、ペプチド抗生物質は、スチュワードシップ・プログラムの一環として、またヘルスケアにおける予防的用途に使用されることが増えており、現代の感染症管理における役割の拡大を強めています。

市場促進要因

ペプチド合成の進歩

主な市場課題

高い開発コスト

主な市場動向

抗菌ペプチド（AMP）に対する意識の高まり

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のペプチド抗生物質市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 種類別（非リボソーム合成ペプチド抗生物質、リボソーム合成ペプチド抗生物質）
  • 投与経路別（注射、経口、局所）
  • 流通チャネル別（病院薬局、オンライン薬局、小売薬局）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 アジア太平洋地域のペプチド抗生物質市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州のペプチド抗生物質市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米のペプチド抗生物質市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米のペプチド抗生物質市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのペプチド抗生物質市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界のペプチド抗生物質市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTEL分析

第16章 競合情勢

• Pfizer Inc.
• Merck & Co., Inc.
• AbbVie Inc
• GSK Plc
• Sandoz International GmbH
• Xellia Pharmaceuticals
• AuroMedics Pharma LLC
• The Menarini Group
• Teva Pharmaceutical Industries Ltd.
• Novartis AG

第17章 戦略的提言

第18章 調査会社について・免責事項

The Global Peptide Antibiotics Market was valued at USD 5.17 Billion in 2024 and is projected to reach USD 7.67 Billion by 2030, growing at a CAGR of 6.79% during the forecast period. Peptide antibiotics are short chains of amino acids with antimicrobial properties, used in the treatment of various infectious diseases. Unlike traditional small-molecule antibiotics, peptide antibiotics consist of larger, protein-like molecules and operate through diverse mechanisms such as membrane disruption or interference with bacterial replication. Their multi-targeted approach reduces the likelihood of bacterial resistance, a key advantage in an era marked by rising antimicrobial resistance. The growing prevalence of infections like Methicillin-resistant Staphylococcus aureus (MRSA), aging populations, increased surgical procedures, and enhanced peptide synthesis technologies are all contributing to the increased demand for these drugs. Moreover, peptide antibiotics are being increasingly used as part of stewardship programs and in prophylactic applications in healthcare, reinforcing their expanding role in modern infectious disease management.

Key Market Drivers

Advancements in Peptide Synthesis

Progress in solid-phase peptide synthesis (SPPS) has significantly enhanced the scalability and efficiency of peptide antibiotic production. Techniques such as the use of Fmoc and Boc protecting groups, multi-segment synthesis, and continuous-flow systems have streamlined complex peptide assembly. Automation has also become prevalent, enabling high-throughput synthesis with precision control. These technological innovations allow for cost-effective and rapid production of complex and stable peptides with enhanced bioactivity. Strategies like native chemical ligation and peptide cyclization further contribute to increased therapeutic efficacy and resistance to enzymatic degradation. Improvements in purification and conjugation methods, as well as the integration of peptides into nanoparticle systems, are expanding the applications of peptide antibiotics in targeted drug delivery and diagnostics, fueling their market expansion.

Key Market Challenges

High Development Costs

The development of peptide antibiotics involves substantial investment across preclinical research, clinical trials, regulatory compliance, and large-scale manufacturing. Early-stage discovery and testing of new peptide candidates demand significant funding for laboratory infrastructure, skilled personnel, and animal studies. Clinical trials-particularly in later stages-incur major costs due to patient recruitment, monitoring, and data collection. Regulatory processes also impose strict requirements for demonstrating safety, efficacy, and quality, further adding to development expenses. Additionally, the cost of peptide production, especially at commercial scale, is elevated due to the complexity of synthesis, quality assurance protocols, and the need for specialized manufacturing equipment. Intellectual property management and ongoing pharmacovigilance activities also contribute to the financial burden, making cost a significant hurdle for widespread adoption.

Key Market Trends

Growing Awareness of Antimicrobial Peptides (AMPs)

Antimicrobial peptides (AMPs) are gaining recognition for their broad-spectrum antimicrobial properties and unique mechanisms of action. Sourced from various organisms, AMPs target a wide range of pathogens and exhibit low resistance development potential. Their dual role in microbial eradication and immune modulation enhances their appeal in infectious disease treatment. The integration of AMPs with traditional antibiotics is being explored to improve therapeutic outcomes and limit resistance. Their application is also expanding into wound care and dermatology due to their healing properties. Increased R&D investment by pharmaceutical companies and a focus on developing AMP-based alternatives to conventional antibiotics reflect the market's shift toward innovative and sustainable antimicrobial solutions.

Key Market Players

• Pfizer Inc.
• Merck & Co., Inc.
• AbbVie Inc
• GSK Plc
• Sandoz International GmbH
• The Menarini Group
• Xellia Pharmaceuticals
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• AuroMedics Pharma LLC

Report Scope:

In this report, the Global Peptide Antibiotics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peptide Antibiotics Market, By Type:

• Non-Ribosomal Synthesized Peptide Antibiotics
• Ribosomal Synthesized Peptide Antibiotics

Peptide Antibiotics Market, By Route of Administration:

• Injectable
• Oral
• Topical

Peptide Antibiotics Market, By Distribution Channel:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Peptide Antibiotics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Peptide Antibiotics Market.

Available Customizations:

Global Peptide Antibiotics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Peptide Antibiotics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Non-Ribosomal Synthesized Peptide Antibiotics, Ribosomal Synthesized Peptide Antibiotics)
  • 5.2.2. By Route of Administration (Injectable, Oral, Topical)
  • 5.2.3. By Distribution Channel (Hospital Pharmacy, Online Pharmacy & Retail Pharmacy)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Peptide Antibiotics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Peptide Antibiotics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. India Peptide Antibiotics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Australia Peptide Antibiotics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Japan Peptide Antibiotics Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Route of Administration
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. South Korea Peptide Antibiotics Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Route of Administration
      • 6.3.5.2.3. By Distribution Channel

7. Europe Peptide Antibiotics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Peptide Antibiotics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Peptide Antibiotics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Spain Peptide Antibiotics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Peptide Antibiotics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. United Kingdom Peptide Antibiotics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Distribution Channel

8. North America Peptide Antibiotics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Peptide Antibiotics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Mexico Peptide Antibiotics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Canada Peptide Antibiotics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Distribution Channel

9. South America Peptide Antibiotics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Peptide Antibiotics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Peptide Antibiotics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Peptide Antibiotics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Peptide Antibiotics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Route of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Peptide Antibiotics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Peptide Antibiotics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Peptide Antibiotics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Peptide Antibiotics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Pfizer Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. Merck & Co., Inc.
• 16.3. AbbVie Inc
• 16.4. GSK Plc
• 16.5. Sandoz International GmbH
• 16.6. Xellia Pharmaceuticals
• 16.7. AuroMedics Pharma LLC
• 16.8. The Menarini Group
• 16.9. Teva Pharmaceutical Industries Ltd.
• 16.10.Novartis AG

17. Strategic Recommendations

18. About Us & Disclaimer